Fig. 3: POU4F1 promoted the resistance of melanoma cells to Vemurafenib. | Cell Death & Disease

Fig. 3: POU4F1 promoted the resistance of melanoma cells to Vemurafenib.

From: POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation

Fig. 3

a The expression level (FPKM values) of POU4F1 in the patients before treatment and after progression with the treatment of dabrafenib. Data were collected from GEO database (GSE50509), n = 16. b The protein level of POU4F1, ERK and phosphorylated ERK and the mRNA level of POU4F1 were analyzed by immunoblotting and qRT-PCR in parental and resistant cells. c. The knockdown and overexpressing efficiency of POU4F1 shRNA and plasmid in parental and resistant cells of A2058 and 451Lu. d Cell viability was evaluated by CCK8 assay in both parental and resistant cells under the treatment of Vemurafenib, n = 3. e Cell colony formation of parental and resistant cells was measured by colony formation assay under the treatment of Vemurafenib, n = 3. Data are presented as the mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001. NC negative control. sh short hairpin RNA. OE over expressing. P parental cells. VR Vemurafenib-resistant cells. Vem Vemurafenib.

Back to article page